---
title: "603590.SH (603590.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603590.SH/news.md"
symbol: "603590.SH"
name: "603590.SH"
parent: "https://longbridge.com/en/quote/603590.SH.md"
datetime: "2026-05-20T05:53:01.389Z"
locales:
  - [en](https://longbridge.com/en/quote/603590.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603590.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603590.SH/news.md)
---

# 603590.SH (603590.SH) — Related News

### [Konruns: Revenue of 915 million yuan in 2025, the annual shareholders' meeting will review multiple proposals](https://longbridge.com/en/news/285527342.md)
*2026-05-07T10:13:40.000Z*
> Konruns expects to achieve operating revenue of 915 million yuan in 2025, a year-on-year increase of 10.87%; net profit 

### [Konruns: The application for the listing permit of the total cyclic ether terpenoid glycosides tablets has been accepted](https://longbridge.com/en/news/283953237.md)
*2026-04-24T07:34:59.000Z*
> Konruns announced that the company recently received the "Acceptance Notice" issued by the National Medical Products Adm

### [Konruns: Presenting preclinical research data for two innovative drugs at the 2026 AACR Annual Meeting](https://longbridge.com/en/news/283784749.md)
*2026-04-23T07:40:52.000Z*
> Konruns announced that it will present preclinical research data for its innovative anti-tumor drugs "KC1086" and "KC110

### [Konruns: Net profit of 47.2136 million yuan in the first quarter of 2026, a year-on-year increase of 6.10%](https://longbridge.com/en/news/283658205.md)
*2026-04-22T11:48:33.000Z*
> Konruns announced that its revenue for the first quarter of 2026 was 215 million yuan, a year-on-year increase of 1.35%;

### [Konruns: The key Phase III clinical study of KC1036 for the second-line treatment of advanced esophageal squamous cell carcinoma has been approved by the CDE](https://longbridge.com/en/news/282170574.md)
*2026-04-09T09:53:11.000Z*
> Konruns announced that its independently developed KC1036 tablets have been approved by the National Medical Products Ad

### [Konruns: Has repurchased 1.4762 million shares, using a total amount of 63.2254 million yuan](https://longbridge.com/en/news/281497522.md)
*2026-04-02T09:23:10.000Z*
> On April 2nd, Konruns announced that by March 2026, the company had repurchased a total of 359,900 shares through centra

### [Konruns: The pivotal Phase III clinical study of KC1036 for the treatment of advanced thymic cancer has been approved by CDE](https://longbridge.com/en/news/279581706.md)
*2026-03-18T10:48:14.000Z*
> Konruns announced that its independently developed KC1036 tablets have been approved by the Center for Drug Evaluation (

### [Overview of A-share Stock Buybacks: Today, 10 Companies Disclosed Buyback Progress](https://longbridge.com/en/news/277847288.md)
*2026-03-04T23:37:39.000Z*
> On March 5th, 10 companies announced their stock repurchase progress, among which 2 companies disclosed their repurchase

### [Konruns: KC1036 combined with PD-1/PD-L1 antibody therapy for advanced solid tumors has received clinical trial approval](https://longbridge.com/en/news/277767546.md)
*2026-03-04T11:07:02.000Z*
> Konruns announced that it has received approval from the National Medical Products Administration to conduct clinical tr